Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Microba Life Sciences Limited ( (AU:MAP) ) just unveiled an update.
Microba Life Sciences Limited has announced a proposed issue of 67,177,796 fully paid ordinary securities, with the issuance date set for June 27, 2025. This move is part of a strategic effort to enhance its capital structure, potentially impacting its market position and offering new opportunities for stakeholders.
The most recent analyst rating on (AU:MAP) stock is a Buy with a A$0.33 price target. To see the full list of analyst forecasts on Microba Life Sciences Limited stock, see the AU:MAP Stock Forecast page.
More about Microba Life Sciences Limited
Microba Life Sciences Limited operates in the biotechnology industry, focusing on microbiome analysis and related services. The company is known for its advanced technology in gut microbiome testing, which offers insights into health and disease management.
Average Trading Volume: 169,236
Technical Sentiment Signal: Sell
Current Market Cap: A$51.5M
See more data about MAP stock on TipRanks’ Stock Analysis page.